Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice

AUTOR(ES)

Bourgeois, C.

FONTE

American Society for Microbiology

RESUMO

Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.

Documentos Relacionados

• An immunocompromised BALB/c mouse model for respiratory syncytial virus infection
• Variants of N-tropic leukemia virus derived from BALB/c mice.
• The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5
• A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice.
• Rearranged immunoglobulin heavy chain variable region (VH) pseudogene that deletes the second complementarity-determining region.